NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

exwannabe,

Patients were matched as best as possible by an external party. The 6% difference in patient category allocation may include biopsy only but is not clear as that category is listed as other or missing. We also do not know the performance scores of those patients and we also know that this small difference can not explain the difference in long tail survival numbers which this small difference in enrollment clearly does not explain especially when those with more residual disease in the treatment arm had better long tail numbers than originally expected. The bias you suggest disparages the independent composer of these ECAs not NWBO as you would imply. I would suggest that there is more to this story that we are not privy to yet that supports the ECAs as composed as there would be no reason to include biopsy only and a greater percentage of patients with residual disease UNLESS other factors were being considered as part of patient comparator balancing. Dr. Linda Liau, Linda Powers and others would see any attempt to sabotage the trial through external comparator bias. Best wishes.